Sun Pharmaceuticals to buy DUSA

A A

Agencies: New Delhi, Nov 08 2012, 19:27 IST

of $13.3 billion, will make a tender offer $8 per share in cash for Dusa, a premium of 38 percent to Dusa's closing price on Wednesday.

Sun Pharma's shares have risen 40 percent this year, compared with a 20 percent rise in the Mumbai market index .

While big multinationals such as Abbott Laboratories and Sanofi SA have been buying out Indian drug companies at high valuations, Sun Pharma remains one of only a few Indian drugmakers that has successfully acquired overseas companies and made profits.

Sun Pharma shares closed down 0.54 percent at 696.55 rupees. The company also announced that its net profit fell 46.5 percent in the second quarter.

Ads by Google

Single Page Format

Previous | 1 | 2 | 3

Shasun Pharma retracts from 52-wk high Sensex, Nifty close up, Bharti shinesSun Pharma shares down Sensex down 56 pts, snaps 6-day rally

Previous Story Google reaches out to the next billion Next Story Not enough for us in reforms: India Inc

Reader's Comments (1)| Post a Comment

Solid synergies, and a fast growing business

Vishal | 09-Nov-2012Reply | Forward

The acquistion would lead to tremendous synergies. The product portfolio of DUSA is growing @25%, which is much faster than the dermat market in the US. Sun would further accelerate the revenue growth by leveraging the field force of their subsidiary Taro, which is a major player in dermatology in the US. This article is extremely informative http://pharmadeals.pharmaintellect.com/2012/11/sun-acquires-dusa-transaction-valuation.html